Список литературы к Главе 19

1. Friman V., Winqvist O., Blimark C. et al. Secondary immunodeficiency in lymphoproliferative malignancies // Hematol. Oncol. 2016. Vol. 34, N 3. P. 121–132.

2. Colovic N., Bogdanovic A., Martinovic­Cemerikic V., Jankovic G. Prognostic significance of serum immunoglobulins in B­chronic lymphocytic leukaemia // Arch. Oncol. 2001. Vol. 9, N 2. P. 4.

3. Dhalla F., Lucas M., Schuh A., Bhole M., Jain R., Patel S.Y. et al. Antibody Deficiency Secondary to Chronic Lymphocytic Leukemia: Should Patients be Treated with Prophylactic Replacement Immunoglobulin? // J. Clin. Immunol. 2014. Vol. 34. P. 277–282.

4. Casulo C., Maragulia J., Zelenetz A.D. Incidence of hypogammaglobulinemia in patients receiving rituximab and the use of intravenous immunoglobulin for recurrent infections // Clin. Lymphoma Myeloma Leuk. 2012. Vol. 13, N 2. P. 106–111.

5. De Angelis F., Tosti M.E., Capria S. et al. Risk of secondary hypogammaglobulinaemia after rituximab and fludarabine in indolent non­Hodgkin lymphomas: a retrospective cohort study // Leuk. Res. 2015. Vol. 39, N 12. P. 1382–1388.

6. Dhalla F., Misbah S.A. Secondary antibody deficiencies // Curr. Opin. Allergy Clin. Immunol. 2015. Vol. 15, N 6. P. 505–513.

7. Hallek M. Chronic lymphocytic leukemia: 2015 update on diagnosis, risk stratification, and treatment // Am. J. Hematol. 2015. Vol. 90, N 5. P. 446–460.

8. Shillitoe B., Hollingsworth R., Foster M., Garcez T., Guzman D., Edgar J.D. et al. Immunoglobulin use in immune deficiency in the UK: a report of the UKPID and National Immunoglobulin Databases // Clin. Med. (Lond.). 2018. Vol. 18, N 5. P. 364–370. DOI: https://doi.org/10.7861/clinmedicine.18­5­364

9. Mallick R., Jolles S., Kanegane H., Agbor­Tarh D., Rojavin M. Treatment satisfaction with subcutaneous immunoglobulin replacement therapy in patients with primary immunodeficiency: a Pooled Analysis of Six Hizentra® Studies // J. Clin. Immunol. 2018. Vol. 38, N 8. P. 886–897. DOI: https://doi.org/10.1007/s10875­018­0562­3 Epub 2018 Nov 21.

10. Gale R.P., Chapel H.M., Bunch C., Rai K.R., Foon K., Courter S.G. et al.; Cooperative Group for the Study of Immunoglobulin in Chronic Lymphocytic Leukemia. Intravenous immunoglobulin for the prevention of infection in chronic lymphocytic leukemia. A randomized, controlled clinical trial. Cooperative group for the study of immunoglobulin in chronic lymphocytic leukemia // N. Engl. J. Med. 1988. Vol. 319. P. 902–907.

11. Raanani P., Gafter­Gvili A., Paul M., Ben­Bassat I., Leibovici L., Shpilberg O. Immunoglobulin prophylaxis in chronic lymphocytic leukemia and multiple myeloma: systematic review and meta­analysis // Leuk. Lymphoma. 2009. Vol. 50. P. 764–772.

12. Chapel H.M., Lee M., Hargreaves R., Pamphilon D.H., Prentice A.G. Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau­phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma // Lancet. 1994. Vol. 343. P. 1059–1063.

13. Compagno N., Malipiero G., Cinetto F., Agostini C. Immunoglobulin replacement therapy in secondary hypogammaglobulinemia // Front. Immunol. 2014. Vol. 5. P. 626.

14. Chapel H., Dicato M., Gamm H., Brennan V., Ries F., Bunch C. et al. Immunoglobulin replacement in patients with chronic lymphocytic leukaemia: a comparison of two dose regimes // Br. J. Haematol. 1994. Vol. 88. P. 209–212.

15. Agostini C., Blau I.W., Kimby E., Plesner T. Prophylactic immunoglobulin therapy in secondary immune deficiency – an expert opinion // Expert Rev. Clin. Immunol. 2016. Vol. 12. P. 921–926.

16. European Medicines Agency. Guideline on core SmPC for human normal immunoglobulin for intravenous administration (IVIg). 2018. URL: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2018/07/WC500252345.pdf

17. Sewell W.A., Kerr J., Behr­Gross M.E., Peter H.H.; Kreuth Ig Working Group. European consensus proposal for immunoglobulin therapies // Eur. J. Immunol. 2014. Vol. 44. P. 2207–2214.

18. Perez E.E., Orange J.S., Bonilla F., Chinen J., Chinn I.K., Dorsey M. et al. Update on the use of immunoglobulin in human disease: a review of evidence // J. Allergy Clin. Immunol. 2017. Vol. 139. P. S1–S46.

19. Tausch E., Stilgenbauer S. Chronic lymphocytic leukemia: current standards and novel approaches // Internist (Berl). 2014. Vol. 55, N 12. P. 1400, 1402–1404, 1406–1409. DOI: https://doi.org/10.1007/s00108­014­3556­0

20. Schuh A.H., Parry­Jones N., Appleby N., Bloor A., Dearden C.E., Fegan C. et al. Guideline for the treatment of chronic lymphocytic leukaemia: a British Society for Haematology Guideline // Br. J. Haematol. 2018.Vol. 182, N 3. P. 344–359. DOI: https://doi.org/10.1111/bjh.15460 Epub 2018 Jul 15.

21. Jolles S., Chapel H., Litzman J. When to initiate immunoglobulin replacement therapy (IGRT) in antibody deficiency: a practical approach // Clin. Exp. Immunol. 2017. Vol. 188, N 3. P. 333–341.

22. Windegger T.M., Nghiem S., Nguyen K.H., Fung Y.L., Scuffham P.A. Primary immunodeficiency disease: a costutility analysis comparing intravenous vs subcutaneous immunoglobulin replacement therapy in Australia // Blood Transfus. 2020. Vol. 18, N 2. P. 96–105.

23. Oscier D., Dearden C., Eren E., Erem E., Fegan C., Follows G. et al. Guidelines on the diagnosis, investigation and management of chronic lymphocytic leukaemia // Br. J. Haematol. 2012. Vol. 159, N 5. P. 541–564.

24. Wolf H.M., Thon V., Litzman J., Eibl M.M. Detection of impaired IgG antibody formation facilitates the decision on early immunoglobulin replacement in hypogammaglobulinemic patients // Front. Immunol. 2015. Vol. 6. P. 32.

25. Kivity S., Katz U., Daniel N., Nussinovitch U., Papageorgiou N., Shoenfeld Y. Evidence for the use of intravenous immunoglobulins – a review of the literature // Clin. Rev. Allergy Immunol. 2010. Vol. 38, N 2–3. P. 201–269.

26. Chérin P., Cabane J. Relevant criteria for selecting an intravenous immunoglobulin preparation for clinical use // BioDrugs. 2010. Vol. 24, N 4. P. 211–223.

27. Abolhassani H., Asgardoon M.H., Rezaei N., Hammarstrom L., Aghamohammadi A. Different brands of intravenous immunoglobulin for primary immunodeficiencies: how to choose the best option for the patient? // Expert Rev. Clin. Immunol. 2015. Vol. 11, N 11. P. 1229–1243.

28. Katz U., Achiron A., Sherer Y., Shoenfeld Y. Safety of intravenous immunoglobulin (IVIG) therapy. Review // Autoimmun. Rev. 2007. Vol. 6, N 4. P. 257–259.

29. Dantal J. Intravenous immunoglobulins: in­depth review of excipients and acute kidney injury risk // Am. J. Nephrol. 2013. Vol. 38, N 4. P. 275–284. DOI: https://doi.org/10.1159/000354893 Epub 2013 Sep 14.

30. Sriaroon P., Ballow M. Immunoglobulin replacement therapy for primary immunodeficiency // Immunol. Allergy Clin. North Am. 2015. Vol. 35, N 4. P. 713–730. DOI: https://doi.org/10.1016/j.iac.2015.07.006